BR112013007849A2 - compostos capazes de modular/preservar a integridade endotelial para uso na prevenção ou tratamento de coagulopatia traumática aguda e parada cardíaca com ressuscitação - Google Patents
compostos capazes de modular/preservar a integridade endotelial para uso na prevenção ou tratamento de coagulopatia traumática aguda e parada cardíaca com ressuscitaçãoInfo
- Publication number
- BR112013007849A2 BR112013007849A2 BR112013007849A BR112013007849A BR112013007849A2 BR 112013007849 A2 BR112013007849 A2 BR 112013007849A2 BR 112013007849 A BR112013007849 A BR 112013007849A BR 112013007849 A BR112013007849 A BR 112013007849A BR 112013007849 A2 BR112013007849 A2 BR 112013007849A2
- Authority
- BR
- Brazil
- Prior art keywords
- modulating
- prevention
- treatment
- compounds capable
- cardiac arrest
- Prior art date
Links
- 206010053567 Coagulopathies Diseases 0.000 title 1
- 208000010496 Heart Arrest Diseases 0.000 title 1
- 230000001154 acute effect Effects 0.000 title 1
- 208000015294 blood coagulation disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000003511 endothelial effect Effects 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 230000000472 traumatic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
- G01N2800/224—Haemostasis or coagulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201070427 | 2010-10-01 | ||
| PCT/DK2011/050375 WO2012041334A1 (en) | 2010-10-01 | 2011-09-30 | Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013007849A2 true BR112013007849A2 (pt) | 2016-06-07 |
Family
ID=44872128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013007849A BR112013007849A2 (pt) | 2010-10-01 | 2011-09-30 | compostos capazes de modular/preservar a integridade endotelial para uso na prevenção ou tratamento de coagulopatia traumática aguda e parada cardíaca com ressuscitação |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20130261177A1 (pt) |
| EP (1) | EP2622354A1 (pt) |
| JP (1) | JP2013543491A (pt) |
| KR (1) | KR20140025303A (pt) |
| CN (2) | CN106038570A (pt) |
| AU (1) | AU2011307494B2 (pt) |
| BR (1) | BR112013007849A2 (pt) |
| CA (1) | CA2812846A1 (pt) |
| WO (1) | WO2012041334A1 (pt) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200028501A (ko) | 2009-06-12 | 2020-03-16 | 맨카인드 코포레이션 | 한정된 비표면적을 갖는 디케토피페라진 마이크로입자 |
| KR20140053881A (ko) * | 2011-04-19 | 2014-05-08 | 릭스하스피탈렛 | 모세관 누출의 예방 및 치료를 위한 수술 동안 투여되는 프로스타시클린 및 그 유사체 |
| US20150057325A1 (en) * | 2012-03-30 | 2015-02-26 | Rigshospitalet | Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest |
| AU2013355130B2 (en) | 2012-12-07 | 2018-06-21 | Cayman Chemical Company Incorporated | Methods of synthesizing a prostacyclin analog |
| US9505737B2 (en) | 2013-01-11 | 2016-11-29 | Corsair Pharma, Inc. | Treprostinil derivative compounds and methods of using same |
| JP6542128B2 (ja) * | 2013-01-11 | 2019-07-10 | コルセア ファーマ インコーポレイテッド | トレプロスチニルのプロドラッグ |
| EP3587404B1 (en) | 2013-03-15 | 2022-07-13 | MannKind Corporation | Microcrystalline diketopiperazine compositions, methods for preparation and use thereof |
| BR112016000937A8 (pt) | 2013-07-18 | 2021-06-22 | Mannkind Corp | formulações farmacêuticas de pó seco, método para a fabricação de uma formulação de pó seco e uso de uma formulação farmacêutica de pó seco |
| KR20160086837A (ko) * | 2013-11-13 | 2016-07-20 | 카이맨 케미칼 컴파니 인코포레이티드 | 프로스타사이클린 유사체의 아민 염 |
| CN107250375A (zh) | 2014-11-06 | 2017-10-13 | 科罗拉多州立大学董事会 | 在血栓溶解剂存在下使用粘弹性分析鉴定新疾病状态 |
| WO2016123163A2 (en) | 2015-01-27 | 2016-08-04 | Kardiatonos, Inc. | Biomarkers of vascular disease |
| CN107430136A (zh) * | 2015-02-03 | 2017-12-01 | 科罗拉多州立大学董事会,公司实体 | 粘弹性分析用于预测大量出血的用途 |
| ES2898424T3 (es) | 2015-03-29 | 2022-03-07 | Endothel Pharma Aps | Una composición que comprende prostaciclina o sus análogos para tratamiento de pacientes críticamente enfermos de modo agudo |
| WO2016200765A1 (en) | 2015-06-08 | 2016-12-15 | The Regents Of The University Of Colorado, A Body Corporate | Time independent viscoelastic analysis parameter for prediction of patient outcome |
| EP3455366A4 (en) | 2016-05-11 | 2020-02-26 | Michael P. Chapman | VISCOELASTIC ANALYSIS OF PATIENTS WITH DISEASES RELATED TO THE CARDIOVASCULAR SYSTEM |
| CN114113641B (zh) * | 2021-10-28 | 2023-11-03 | 中科精瓒(武汉)医疗技术有限公司 | 一种活化凝血检测试剂及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58164512A (ja) * | 1982-03-25 | 1983-09-29 | Ono Pharmaceut Co Ltd | プロスタグランジン類似化合物を有効成分として含有する肝臓疾患治療剤 |
| AU4405293A (en) * | 1992-06-05 | 1994-01-04 | Barbara M. Alving | Test for quantitative thrombin time |
| JPH11322612A (ja) * | 1998-03-13 | 1999-11-24 | Toray Ind Inc | 肝細胞増殖因子誘引剤 |
| CN2757804Y (zh) * | 2004-11-19 | 2006-02-15 | 杨俊玉 | 心脏按压复苏指示装置 |
| EP2063273A1 (en) * | 2007-11-21 | 2009-05-27 | Pentapharm GmbH | Method for assessing the fibrinogen contribution in coagulation |
| US20100144597A1 (en) * | 2008-12-10 | 2010-06-10 | Ward Kevin R | Novel combinatorial approaches to enhancing oxygen transport to tissues |
| RU2011132125A (ru) * | 2008-12-30 | 2013-02-10 | Тромбологик Апс | Способы идентификации критических пациентов с повышенным риском развития органной недостаточности и соединения для их лечения |
| EP2525806B1 (en) * | 2010-01-20 | 2014-06-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Angiopoietin-like-protein-4 (ANGPTL4) for the preservation of vascular endothelial-cell barrier integrity |
-
2011
- 2011-09-30 AU AU2011307494A patent/AU2011307494B2/en not_active Ceased
- 2011-09-30 CA CA2812846A patent/CA2812846A1/en not_active Abandoned
- 2011-09-30 BR BR112013007849A patent/BR112013007849A2/pt not_active IP Right Cessation
- 2011-09-30 EP EP11773168.7A patent/EP2622354A1/en not_active Withdrawn
- 2011-09-30 JP JP2013530571A patent/JP2013543491A/ja active Pending
- 2011-09-30 CN CN201610390867.1A patent/CN106038570A/zh active Pending
- 2011-09-30 US US13/877,285 patent/US20130261177A1/en not_active Abandoned
- 2011-09-30 WO PCT/DK2011/050375 patent/WO2012041334A1/en active Application Filing
- 2011-09-30 KR KR1020137010342A patent/KR20140025303A/ko not_active Application Discontinuation
- 2011-09-30 CN CN201180057292.7A patent/CN103238070B/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011307494B2 (en) | 2015-08-06 |
| EP2622354A1 (en) | 2013-08-07 |
| CN106038570A (zh) | 2016-10-26 |
| CN103238070B (zh) | 2016-06-29 |
| AU2011307494A1 (en) | 2013-05-02 |
| US20130261177A1 (en) | 2013-10-03 |
| CA2812846A1 (en) | 2012-04-05 |
| JP2013543491A (ja) | 2013-12-05 |
| WO2012041334A1 (en) | 2012-04-05 |
| CN103238070A (zh) | 2013-08-07 |
| KR20140025303A (ko) | 2014-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013007849A2 (pt) | compostos capazes de modular/preservar a integridade endotelial para uso na prevenção ou tratamento de coagulopatia traumática aguda e parada cardíaca com ressuscitação | |
| IL244995B (en) | A pharmaceutical composition containing a pcsk9 inhibitor in the treatment of hyperlipidemia | |
| HK1214765A1 (zh) | 包含 抑制劑和組蛋白脫乙酰基酶抑制劑的藥物組合以及其在治療增生性疾病中的用途 | |
| BR112013033940A2 (pt) | terapia combinada compreendendo um inibidor de cdk4/6 e um inibidor de pi3k para uso no tratamento de câncer | |
| EP3402500A4 (en) | COMBINATION THERAPY OF ONCOLYTIC VIRUS AND CHECKPOINT INHIBITOR | |
| ZA201307829B (en) | Hydrocellular absorbent dressing and uses thereos for the treatemt of chronic and acute wounds | |
| BR112012031194A2 (pt) | derivados de cisteamina e seu uso no tratamento de ehna | |
| HK1179511A1 (zh) | 用於預防和/或治療術後疼痛的 配體 | |
| CL2014000732A1 (es) | Compuestos derivados heterociclicos para su uso en la prevencion o tratamiento de una infeccion por flavivirus; metodo para su preparacion; y composicion farmaceutica que los comprende. | |
| IL218644A0 (en) | Pharmaceutical composition having the active substances metformin and sitaglipin or vildagliptin | |
| BRPI1013288A2 (pt) | uso de um composto, método de composição farmacêutica para o tratamento de doenças em que a motilidade gastrointestinal anormal está envolvida, kit e embalagem comercial que compreende uma composição farmacêutica contendo o composto | |
| BR112015002706A2 (pt) | niclosamida e seus derivados para uso no tratamento de tumores sólidos | |
| HK1204928A1 (en) | Inhibitors of the notch signalling pathway and secretion for use in medicine notch | |
| PL2905268T3 (pl) | Kompozycja do traktowania stref zaszpachlowanych gipsem, wykańczanych gipsem albo tynkowanych gipsem i jej zastosowanie do traktowania stref zaszpachlowanych gipsem, wykańczanych gipsem albo tynkowanych gipsem | |
| BR112014009456A2 (pt) | uso de melatonina para o tratamento e/ou prevenção de mucosite | |
| BR112013014189A2 (pt) | composição farmacêutica que compreende transcinamaldeíco e o uso da mesma no tratamento de infecções | |
| FR2999428B1 (fr) | Chitine ou derives de chitine pour utilisation dans la prevention et/ou le traitement de parasitoses | |
| SG11202111820PA (en) | Oncolytic adenovirus and checkpoint inhibitor combination therapy | |
| ES2660494T8 (es) | Uso de levocetirizina y montelukast en el tratamiento de una lesión traumática | |
| BR112015027026A8 (pt) | composição para uso na redução da formação de casca e na promoção da cicatrização | |
| CL2014002398A1 (es) | Formulación que comprende clonostachys rosea combinado con un silicato de calcio en partículas; y uso para tratar hongos patógenos en plantas | |
| PL2925131T3 (pl) | Synergistyczna kombinacja lenacylu i jednego spośród DCOIT lub OIT do suchej powłoki ochronnej | |
| CL2015000333A1 (es) | Azaheterociclos inhibidores de bir2 y/o bir3; composicion farmaceutica; y uso en el tratamiento del cancer. | |
| PL2925132T3 (pl) | Synergistyczna kombinacja lenacylu i lPBC do suchej powłoki ochronnej | |
| BR112014003118A2 (pt) | composto que induz atividade de cardiotrofina-1 (ct-1) para uso na prevenção e/ou tratamento de lesão renal aguda, composição e uso de uma composição |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2481 DE 24-07-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |